Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 12

1.

Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.

Kanodia JS, Gadkar K, Bumbaca D, Zhang Y, Tong RK, Luk W, Hoyte K, Lu Y, Wildsmith KR, Couch JA, Watts RJ, Dennis MS, Ernst JA, Scearce-Levie K, Atwal JK, Ramanujan S, Joseph S.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):283-91. doi: 10.1002/psp4.12081. Epub 2016 May 17.

2.

Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans.

Ling IF, Golde TE, Galasko DR, Koo EH.

Alzheimers Res Ther. 2015 Aug 5;7(1):55. doi: 10.1186/s13195-015-0137-y. eCollection 2015.

3.

Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans.

Elbert DL, Patterson BW, Bateman RJ.

Math Biosci. 2015 Mar;261:48-61. doi: 10.1016/j.mbs.2014.11.004. Epub 2014 Dec 9.

4.

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage.

Portelius E, Dean RA, Andreasson U, Mattsson N, Westerlund A, Olsson M, Demattos RB, Racke MM, Zetterberg H, May PC, Blennow K.

Alzheimers Res Ther. 2014 Nov 17;6(5-8):75. doi: 10.1186/s13195-014-0075-0. eCollection 2014.

5.

CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.

Dobrowolska JA, Michener MS, Wu G, Patterson BW, Chott R, Ovod V, Pyatkivskyy Y, Wildsmith KR, Kasten T, Mathers P, Dancho M, Lennox C, Smith BE, Gilberto D, McLoughlin D, Holder DJ, Stamford AW, Yarasheski KE, Kennedy ME, Savage MJ, Bateman RJ.

J Neurosci. 2014 Jun 11;34(24):8336-46. doi: 10.1523/JNEUROSCI.0540-14.2014.

6.

Alzheimer's disease biomarkers in animal models: closing the translational gap.

Sabbagh JJ, Kinney JW, Cummings JL.

Am J Neurodegener Dis. 2013 Jun 21;2(2):108-20. Print 2013.

7.

Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers.

Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ.

Sci Transl Med. 2013 Jun 12;5(189):189ra77. doi: 10.1126/scitranslmed.3005615.

8.

Interplay between α-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor.

Ortega F, Stott J, Visser SA, Bendtsen C.

J Biol Chem. 2013 Jan 11;288(2):785-92. doi: 10.1074/jbc.M112.419135. Epub 2012 Nov 14.

9.

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ.

J Alzheimers Dis. 2012;31(2):335-41. doi: 10.3233/JAD-2012-120508.

10.

BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system.

Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E.

PLoS One. 2012;7(2):e31084. doi: 10.1371/journal.pone.0031084. Epub 2012 Feb 6.

11.

The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease.

Portelius E, Fortea J, Molinuevo JL, Gustavsson MK, Andreasson U, Sanchez-Valle R.

Mol Med Rep. 2012 Apr;5(4):1111-5. doi: 10.3892/mmr.2012.774. Epub 2012 Feb 1.

12.

Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.

Halim A, Brinkmalm G, Rüetschi U, Westman-Brinkmalm A, Portelius E, Zetterberg H, Blennow K, Larson G, Nilsson J.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11848-53. doi: 10.1073/pnas.1102664108. Epub 2011 Jun 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk